Page last updated: 2024-10-17

aminocaproic acid and Pregnancy

aminocaproic acid has been researched along with Pregnancy in 33 studies

Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.

Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.

Research Excerpts

ExcerptRelevanceReference
" We sought to determine the impact of tranexamic acid and ɛ-aminocaproic acid on in vitro clotting properties in pregnancy."3.85Using antifibrinolytics in the peripartum period - concern for a hypercoagulable effect? ( Ahmadzia, HK; Grotegut, CA; Hoffman, MR; James, AH; Lockhart, EL; Murtha, AP; Swamy, GK; Thomas, SM; Welsby, IJ, 2017)
"Administration of epsilon-aminocaproic acid, a fibrinolytic inhibitor, either orally or from an impregnated IUD, had no effect on numbers of implanted embryos, their viability, or their diameters at Day 10 of pregnancy."3.66Effects of epsilon-aminocaproic acid on fertility in the rabbit. ( Aaronson, DE; Andrade, AT; Guerra, MO; Shaw, ST, 1978)
" On the other hand, AIHA did not affect the total length of oestrous cycle at the same dosage level used to interrupt pregnancy."1.29Antifertility effects of (+)-S-2-amino-6-iodoacetamidohexanoic acid (2-AIHA) in female rats. ( Ceballos, G; Chamorro, G; Munoz, O; Salazar, M; Salazar, S; Trujillo, J; Yanez, R, 1996)
"Hematuria is a rather frequent complication in patients with sickling disorders."1.27Sickle-cell-induced hematuria in pregnancy. The current diagnostic and therapeutic approach. ( Fadel, HE; Hadi, HA; Kassam, SH; Milner, PF; Sanchez-Ramos, L, 1984)
"A fibrin slide test was utilized to study cutaneous vascular plasminogen activator activity in normal rabbit, rat, monkey, and human skin and in rabbit skin following development of the local Shwartzman reaction and after substituting epsilon-aminocaproic acid for the preparatory injection of endotoxin in the local Shwartzman reaction."1.26Cutaneous vascular fibrinolytic activity in the local Shwartzman reaction. ( Bergstein, JM, 1977)

Research

Studies (33)

TimeframeStudies, this research(%)All Research%
pre-199026 (78.79)18.7374
1990's4 (12.12)18.2507
2000's0 (0.00)29.6817
2010's3 (9.09)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ortmann, E1
Besser, MW1
Klein, AA1
de Maat, S1
Björkqvist, J1
Suffritti, C1
Wiesenekker, CP1
Nagtegaal, W1
Koekman, A1
van Dooremalen, S1
Pasterkamp, G1
de Groot, PG1
Cicardi, M1
Renné, T1
Maas, C1
Ahmadzia, HK1
Lockhart, EL1
Thomas, SM1
Welsby, IJ1
Hoffman, MR1
James, AH1
Murtha, AP1
Swamy, GK1
Grotegut, CA1
HOEDT, HT1
ROTH, F1
ALBRECHTSEN, OK1
SKJODT, P1
SOULIER, JP1
MARZETTI, L3
MORINI, A1
SUREAU, C1
CANNON, M1
BENAGIANO, G1
LAGRUE, G1
MILLIEZ, P1
FLUTE, PT1
GRAEBER, W1
BACH, HG1
LAU, H1
SACKREUTHER, W1
SHARP, AA1
BONNAR, J1
CRAWFORD, JM1
MAKI, M1
KIKUCHI, K1
WATANABE, S1
KIKUCHI, E1
SKVARIL, F2
GRUENBERGER, D1
DREVO, M1
SLONIM, D1
STRAUSS, J1
OPPELT, HG1
BECK, L1
ADAM, E1
Niznikowska-Marks, MJ2
Oknińska, A2
Gawlik, Z2
Ostojska, J2
Grygalewicz, J2
Galczak, W2
Dubin, NH1
Cummings, DB1
Blake, DA1
King, TM1
Kassam, SH1
Hadi, HA1
Fadel, HE1
Sanchez-Ramos, L1
Milner, PF1
Linnikov, VI1
Chamorro, G1
Salazar, M1
Salazar, S1
Ceballos, G1
Trujillo, J1
Munoz, O1
Yanez, R1
Alexandrov, VA1
Bespalov, VG2
Petrov, AS2
Troyan, DN1
Bergstein, JM1
Andrade, AT1
Shaw, ST1
Guerra, MO1
Aaronson, DE1
Tucci, PL1
Biagioli, EC1
Panero, C1
Aleksandrov, VA1
Troian, DN1
Peng, TC1
Kickler, TS1
Bell, WR1
Haller, E1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Evaluation of the Minimum Concentration of Tranexamic Acid Required to Inhibit Fibrinolysis in a Population of Pregnant Women at Term.[NCT02579941]40 participants (Actual)Interventional2015-11-30Completed
Prophylactic Use of Topical Tranexamic Acid to Aid Surgical Haemostasis During Caesarean Sections in Parturients With Moderate to High Risk of Bleeding[NCT02492087]Phase 384 participants (Anticipated)Interventional2015-08-31Recruiting
Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial[NCT03364491]Phase 311,000 participants (Actual)Interventional2018-03-15Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Hemoglobin

[Key secondary outcome] Change in hemoglobin from the most recent measured before delivery to lowest measured in the 48 hours after delivery (NCT03364491)
Timeframe: from 4 weeks before delivery to 48 hours postpartum

Interventiongrams per deciliter (Mean)
Tranexamic Acid-1.8
Placebo-1.9

Length of Stay

Mother's length of stay from delivery to discharge (NCT03364491)
Timeframe: Until hospital discharge, an average of 3 days

Interventiondays (Median)
Tranexamic Acid3
Placebo3

Number of Mothers Who Died or Had Thromboembolic Events (Venous or Arterial), Ischemic Stroke, Myocardial Infarction, New-onset Seizure Activity, or Were Admitted to the Intensive Care Unit for More Than 24 Hours

(NCT03364491)
Timeframe: within 6 weeks postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid35
Placebo32

Number of Participants Who Received Open Label TXA or Other Antifibrinolytic

This is the number of mothers who were treated with any amount of open-label TXA (not blinded study drug) or another antifibrinolytic (eg., Amicar) (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid108
Placebo109

Number of Participants Who Received Surgical or Radiologic Interventions to Control Bleeding and Related Complications

This is the number of mothers who required any of the following types of surgical procedures to control bleeding: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid233
Placebo231

Number of Participants Who Received Treatments and Interventions in Response to Bleeding and Related Complications

[Key secondary outcome] This is the number of mothers who received treatments and interventions to control bleeding such as: uterotonics such as prostaglandins or methergine, but excluding oxytocin; open label TXA or other antifibrinolytics; transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates; laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid892
Placebo986

Number of Participants Who Were Transfused With 4 or More Units of Packed Red Blood Cells

Participants were categorized according to the amount of packed red blood cells or whole blood transfused, either as 0 to 3 units, or 4 or more units (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid20
Placebo19

Number of Participants Who Were Transfused With Other Blood Products

This is the number of mothers who received during the first 7 days after delivery a transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets, or received any factor concentrates (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid29
Placebo31

Number of Participants Who Were Treated With Uterotonics Other Than Oxytocin

This is the number of mothers who were treated with uterotonics such as prostaglandins or methergine, but excluding oxytocin, from delivery through 48 hours after delivery. (NCT03364491)
Timeframe: within 48 hours postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid649
Placebo732

Number of Participants With a Thromboembolic Event (Venous or Arterial), Ischemic Stroke, or Myocardial Infarction

[Key secondary outcome] This is the number of mothers who experienced a thromboembolic event, ischemic stroke, or myocardial infarction during the 6 weeks after delivery. (NCT03364491)
Timeframe: within 6 weeks postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid12
Placebo13

Number of Participants With Estimated Blood Loss Greater Than 1 Liter During Delivery

[Major secondary outcome] The surgeon or anesthesiologist estimated the blood loss during the delivery in milliliters, which was recorded in the anesthesia record and/or operative report (NCT03364491)
Timeframe: From skin incision to transfer from operating room, average of 1 hour

InterventionParticipants (Count of Participants)
Tranexamic Acid339
Placebo368

Number of Participants With Maternal Death or Transfusion of Packed Red Blood Cells

Participants were monitored from delivery until hospital discharge or 7 days after delivery (postpartum), whichever is sooner. This is the number of mothers who died for any reason, or had a blood transfusion of 1 or more units (of packed red blood cells, including whole blood or cell saver). (NCT03364491)
Timeframe: by hospital discharge or by 7 days postpartum, whichever is sooner

InterventionParticipants (Count of Participants)
Tranexamic Acid201
Placebo233

Number of Participants With Postpartum Infectious Complications

[Key Secondary Outcome] This is the number of mothers who experienced any of the following infectious complications in the 6 weeks after delivery: endometritis, surgical site infection, pelvic abscess (NCT03364491)
Timeframe: within 6 weeks postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid162
Placebo125

Number of Participants With Seizure Activity That Was Not Seen Prior to Study Enrollment

This is the number of mothers who experienced seizure activity, confirmed by central review, whose onset is after enrollment (NCT03364491)
Timeframe: within 6 weeks postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid2
Placebo0

Reviews

3 reviews available for aminocaproic acid and Pregnancy

ArticleYear
Antifibrinolytic agents in current anaesthetic practice.
    British journal of anaesthesia, 2013, Volume: 111, Issue:4

    Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced

2013
Antifibrinolytic agents in current anaesthetic practice.
    British journal of anaesthesia, 2013, Volume: 111, Issue:4

    Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced

2013
Antifibrinolytic agents in current anaesthetic practice.
    British journal of anaesthesia, 2013, Volume: 111, Issue:4

    Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced

2013
Antifibrinolytic agents in current anaesthetic practice.
    British journal of anaesthesia, 2013, Volume: 111, Issue:4

    Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced

2013
[NEPHROLOGY IN 1964].
    La Revue du praticien, 1964, Jun-21, Volume: 14

    Topics: Acute Kidney Injury; Aminocaproates; Aminocaproic Acid; Antineoplastic Agents; Diabetes Mellitus; Di

1964
PATHOLOGICAL FIBRINOLYSIS.
    British medical bulletin, 1964, Volume: 20

    Topics: Aminocaproates; Aminocaproic Acid; Anticoagulants; Blood Coagulation Disorders; Blood Group Incompat

1964

Other Studies

30 other studies available for aminocaproic acid and Pregnancy

ArticleYear
Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations.
    The Journal of allergy and clinical immunology, 2016, Volume: 138, Issue:5

    Topics: Aminocaproic Acid; Angioedemas, Hereditary; Antifibrinolytic Agents; Bradykinin; Complement C1 Inhib

2016
Using antifibrinolytics in the peripartum period - concern for a hypercoagulable effect?
    Journal of neonatal-perinatal medicine, 2017, Volume: 10, Issue:1

    Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Blood Coagulation; Case-Control Studies; Female;

2017
[Case of amniotic fluid embolism treated with ypsilon-amino-caproic acid].
    Nederlandsch tijdschrift voor verloskunde en gynaecologie, 1962, Volume: 62

    Topics: Aminocaproates; Aminocaproic Acid; Amniotic Fluid; Caproates; Embolism; Embolism, Amniotic Fluid; Fe

1962
[Orientation on the effect of 6-aminocaproic acid in obstetrics and gynecology].
    Therapeutische Umschau. Revue therapeutique, 1962, Volume: 19

    Topics: Amino Acids; Aminocaproic Acid; Blood Coagulation Disorders; Caproates; Gynecology; Obstetrics; Preg

1962
Treatment of haemorrhagic diathesis by epsilon-amino-caproic acid and human fibrinogen in a case of abruptio placentae.
    Danish medical bulletin, 1962, Volume: 9

    Topics: Abruptio Placentae; Afibrinogenemia; Amino Acids; Aminocaproic Acid; Antifibrinolytic Agents; Caproa

1962
[HEMORRHAGIC SYNDROME IN LABOR].
    Geburtshilfe und Frauenheilkunde, 1963, Volume: 23

    Topics: Afibrinogenemia; Aminocaproates; Aminocaproic Acid; Aprotinin; Enzyme Inhibitors; Female; Fibrinolys

1963
[THE USE OF INJECTABLE FIBRINOGEN IN SURGERY AND OBSTETRICS].
    Sangre, 1963, Volume: 42

    Topics: Afibrinogenemia; Aminocaproates; Aminocaproic Acid; Coagulants; Enzyme Inhibitors; Female; Fibrinoge

1963
[OBSTETRICAL HEMORRHAGIC SYNDROMES. OBSERVATIONS AND CONSIDERATIONS OF A PHYSIOPATHOLOGICAL, CLINICAL AND THERAPEUTIC NATURE].
    Minerva ginecologica, 1964, Feb-15, Volume: 16

    Topics: Aminocaproates; Aminocaproic Acid; Blood Coagulation Disorders; Blood Coagulation Tests; Cesarean Se

1964
[FIBRINOLYSIS IN OBSTETRICS. EVOLUTION OF CONCEPTS AND THERAPEUTICS. IS ITS PREVENTION POSSIBLE?].
    Maternite; revue pratique d'obstetrique et de puericulture, 1964, Volume: 13

    Topics: Afibrinogenemia; Aminocaproates; Aminocaproic Acid; Diagnosis; Female; Fibrinolysis; Humans; Obstetr

1964
[TREATMENT OF HEMORRHAGIC DISEASES WITH EPSILON-AMINOCAPROIC ACID IN OBSTETRICS AND GYNECOLOGY].
    La Clinica ostetrica e ginecologica, 1964, Volume: 66

    Topics: Afibrinogenemia; Aminocaproates; Aminocaproic Acid; Blood Coagulation Factors; Endometritis; Erythro

1964
[ON A CASE OF MASSIVE HEMATURIA OCCURRING WITHOUT APPARENT CAUSE AFTER SPONTANEOUS DELIVERY].
    La Clinica ostetrica e ginecologica, 1964, Volume: 66

    Topics: Aminocaproates; Aminocaproic Acid; Delivery, Obstetric; Drug Therapy; Female; Hematuria; Humans; Lab

1964
HAEMORRHAGE AND FIBRINOLYSIS.
    Proceedings of the Royal Society of Medicine, 1964, Volume: 57

    Topics: Aminocaproates; Aminocaproic Acid; Amniotic Fluid; Blood Coagulation Disorders; Blood Coagulation Te

1964
[HYPOFIBRINOGENEMIC HEMORRHAGE IN PREMATURE SEPARATION OF THE PLACENTA].
    Gynaecologia. International monthly review of obstetrics and gynecology. Revue internationale mensuelle d'obstetrique et de gynecologie. Monatsschrift fur Geburtshilfe und Gynakologie, 1964, Volume: 158

    Topics: Abruptio Placentae; Afibrinogenemia; Aminocaproates; Aminocaproic Acid; Blood Coagulation Tests; Blo

1964
HAEMORRHAGIC DIATHESIS DUE TO ABRUPTIO PLACENTAE TREATED BY FIBRINOGEN, EPSILON-AMINOCAPROIC ACID, AND HYSTEROTOMY.
    Lancet (London, England), 1965, Jan-30, Volume: 1, Issue:7379

    Topics: Abruptio Placentae; Aminocaproates; Aminocaproic Acid; Blood Coagulation Tests; Blood Platelets; Blo

1965
A COAGULATION ANOMALY: PLASMA BEING MADE NON-CLOTTABLE BY ADDING THROMBIN, AND CLOTTABLE BY THROMBOPLASTIN-CALCIUM OR TOLUIDINE BLUE-THROMBIN.V5 BLUE-THROMBIN.
    The Tohoku journal of experimental medicine, 1964, Dec-25, Volume: 84

    Topics: Abruptio Placentae; Afibrinogenemia; Aminocaproates; Aminocaproic Acid; Blood Coagulation Tests; Blo

1964
[FATE OF ANTIBODIES DURING THE COURSE OF SPONTANEOUS CLEAVAGE OF PLACENTAL GAMMA GLOBULIN AND THE INHIBITORY EFFECT OF EPSILON-AMINOCAPROIC ACID (EACA)].
    Ceskoslovenska epidemiologie, mikrobiologie, imunologie, 1964, Volume: 13

    Topics: Aminocaproates; Aminocaproic Acid; Antibodies; Enterovirus C, Human; Female; gamma-Globulins; Immuno

1964
[BLOOD COAGULATION DISORDERS DURING LABOR WITH SPECIAL REFERENCE TO FIBRINOLYSIS].
    Geburtshilfe und Frauenheilkunde, 1965, Volume: 25

    Topics: Aminocaproates; Aminocaproic Acid; Blood Coagulation Disorders; Drug Therapy; Female; Fibrinogen; Fi

1965
THE USE OF PLACENTAL GAMMA GLOBULINS STABILIZED WITH THE EPSILON-AMINOCAPROIC ACID FOR THE PREVENTION OF MEASLES.
    Archiv fur die gesamte Virusforschung, 1965, Volume: 16

    Topics: Aminocaproates; Aminocaproic Acid; Biomedical Research; Female; gamma-Globulins; Humans; Measles; Ph

1965
[Studies on the effect of oral contraceptives and epsilon-aminocaproic acid on pregnant rats and their fetuses with particular attention to the coagulation tests].
    Pediatria polska, 1980, Volume: 55, Issue:7

    Topics: Afibrinogenemia; Aminocaproates; Aminocaproic Acid; Animals; Blood Coagulation Tests; Chlormadinone

1980
[Effect of oral contraceptives and epsilon-aminocaproic acid on pregnant female rats and their fetuses. Histopathologic study].
    Patologia polska, 1981, Volume: 32, Issue:1

    Topics: Abnormalities, Drug-Induced; Aminocaproates; Aminocaproic Acid; Animals; Chlormadinone Acetate; Cont

1981
Effect of epsilon amino caproic acid, a fibrinolytic inhibitor, on implantation and fetal viability in the rat.
    Biology of reproduction, 1980, Volume: 23, Issue:3

    Topics: Aminocaproates; Aminocaproic Acid; Animals; Dose-Response Relationship, Drug; Embryo Implantation; F

1980
Sickle-cell-induced hematuria in pregnancy. The current diagnostic and therapeutic approach.
    The Journal of reproductive medicine, 1984, Volume: 29, Issue:2

    Topics: Adolescent; Adult; Aminocaproates; Aminocaproic Acid; Anemia, Sickle Cell; Female; Fluid Therapy; He

1984
[Experimental effect of E-aminocaproic acid on fetal hemorrhages].
    Pediatriia akusherstvo i ginekologiia, 1980, Issue:3

    Topics: Aminocaproates; Aminocaproic Acid; Animals; Drug Evaluation, Preclinical; Female; Fetal Membranes, P

1980
Antifertility effects of (+)-S-2-amino-6-iodoacetamidohexanoic acid (2-AIHA) in female rats.
    Contraception, 1996, Volume: 53, Issue:4

    Topics: Abortifacient Agents; Aminocaproates; Aminocaproic Acid; Animals; Arginase; Contraceptives, Oral; Em

1996
Study of post-natal effect of chemopreventive agents on ethylnitrosourea-induced transplacental carcinogenesis in rats. III. Inhibitory action of indomethacin, voltaren, theophylline and epsilon-aminocaproic acid.
    Carcinogenesis, 1996, Volume: 17, Issue:9

    Topics: Aminocaproic Acid; Animals; Anticarcinogenic Agents; Brain Neoplasms; Carcinogens; Central Nervous S

1996
Cutaneous vascular fibrinolytic activity in the local Shwartzman reaction.
    The American journal of pathology, 1977, Volume: 88, Issue:3

    Topics: Aminocaproic Acid; Animals; Blood Vessels; Female; Fibrin; Fibrinolysis; Haplorhini; Humans; In Vitr

1977
Effects of epsilon-aminocaproic acid on fertility in the rabbit.
    Journal of reproduction and fertility, 1978, Volume: 52, Issue:2

    Topics: Aminocaproates; Aminocaproic Acid; Animals; Embryo Implantation; Female; Fertility; Intrauterine Dev

1978
Proteolytic activity of maternal serum on newborn IgD-positive lymphocytes. Study with protease inhibitors.
    Biology of the neonate, 1978, Volume: 34, Issue:1-2

    Topics: Aminocaproic Acid; Blood; Female; Humans; Immunoglobulin D; Infant, Newborn; Lymphocytes; Pregnancy;

1978
[The inhibiting effect of epsilon-aminocaproic acid on the incidence of induced tumors of the esophagus, nervous system and kidneys].
    Voprosy onkologii, 1992, Volume: 38, Issue:1

    Topics: Aminocaproic Acid; Animals; Anticarcinogenic Agents; Carcinogens; Chi-Square Distribution; Dimethyln

1992
Obstetric complications in a patient with Bernard-Soulier syndrome.
    American journal of obstetrics and gynecology, 1991, Volume: 165, Issue:2

    Topics: Adult; Aminocaproic Acid; Bernard-Soulier Syndrome; Female; gamma-Globulins; Humans; Immunity, Mater

1991